Borsa di ricerca di 11 mesi dal titolo: “The role of anti TNF alpha agents in Behcet’s disease refractory to standard of care therapies: multicenter randomized controlled prospective parallel group single-blind trial to evaluate the 6month effectiveness of either infliximab or adalimumab”

Bando Borsa prot. 6582 Scadenza presentazione domande 30/05/2020 Ore 12.30 Approvaz.atti 6582…

Leggi tutto…